GlassScriptPhysician profile
Nicole Leah Lanman
NPI 1063413201
$299.09
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $88.23 · 2021: $35.03 · 2022: $39.40.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $66.93 | 2019-2022 | |
| Tris Pharma INC | $61.46 | 2019 | |
| Genentech USA, INC. | $42.19 | 2020 | |
| Corium, LLC | $23.14 | 2022 | |
| Welch Allyn | $17.62 | 2021 | |
| Sanofi Pasteur INC. | $17.41 | 2021 | |
| Glaxosmithkline, LLC. | $16.18 | 2019 | |
| Merck Sharp & Dohme LLC | $15.37 | 2019 | |
| Adlon Therapeutics L.P. | $13.81 | 2019 | |
| Shire North American Group INC | $12.91 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.07 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Lanman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.